Christopher Marshall

Christopher Marshall is a visionary leader in the biotechnology sector, currently serving as the Co-founder, President, and CEO of Calder Biosciences Inc. With a robust background in biochemistry and molecular biology, Christopher has been instrumental in spearheading innovative projects that address critical health challenges. At Calder Biosciences, he focuses on developing cutting-edge vaccine enabling technologies designed to enhance the performance of vaccine immunogens. His leadership has been pivotal in navigating the complexities of product development, ensuring that the company remains at the forefront of vaccine research and development.

Under Christopher’s guidance, Calder Biosciences is dedicated to creating highly potent vaccines that offer protection against some of the most insidious infectious diseases. His entrepreneurial spirit and deep expertise in drug discovery and assay development have allowed the company to streamline its processes, reduce development risks, and accelerate the path from concept to market. Christopher’s commitment to wellness and public health drives the mission of Calder Biosciences, as he collaborates with a talented team of scientists and industry professionals to bring transformative solutions to global health challenges.

In addition to his work at Calder, Christopher co-founded Ophidion, Inc., where he leverages technology licensed from Rockefeller University and HHMI to tackle cognitive impairment, anxiety, depression, and pain. This innovative approach not only enhances target specificity and drug efficacy but also significantly lowers the risk of addiction, showcasing his dedication to developing safer therapeutic options. With a comprehensive skill set that includes valuation, intellectual property management, and genetics, Christopher Marshall continues to make a profound impact on the life sciences landscape, driving forward the mission of improving health outcomes through innovative biotechnology solutions.